An overview of the determinants of CCR5 and CXCR4 co-receptor function

Journal of General Virology

Volumn 82, Issue 8, 2001, Pages 1807-1814

  Dragic, T ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; G PROTEIN COUPLED RECEPTOR; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS GLYCOPROTEIN 120; VIRUS GLYCOPROTEIN 41;

AMINO TERMINAL SEQUENCE; HUMAN IMMUNODEFICIENCY VIRUS 1; MOUSE; NONHUMAN; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; RAT; REVIEW; TARGET CELL;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0034906440     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/0022-1317-82-8-1807     Document Type: Review

References (111)

1. CC chemokine receptor 5-mediated signaling and HIV-1 co-receptor activity share common structural determinants. Critical residues in the third extracellular loop support HIV-1 fusion
2. HIV-1 coreceptor activity of CCR5 and its inhibition by chemokines: Independence from G protein signaling and importance of coreceptor downmodulation
3. HIV coreceptor downregulation as antiviral principle: SDF-1alpha-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication
4. T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure
5. Multiple extracellular elements of CCR5 and HIV-1 entry: Dissociation from response to chemokines
6. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity
7. Human immunodeficiency virus (HIV) envelope binds to CXCR4 independently of CD4, and binding can be enhanced by interaction with soluble CD4 or by HIV envelope deglycosylation
8. Patterns of CCR5, CXCR4, and CCR3 usage by envelope glycoproteins from human immunodeficiency virus type 1 primary isolates
9. The CCR5 deletion mutation fails to protect against multiple sclerosis
10. HIV entry and tropism: The chemokine receptor expression
11. A new classification for HIV-1
12. HIV-1-induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR-5 co-receptor
13. Multiple charged and aromatic residues in CCR5 amino-terminal domain are involved in high affinity binding of both chemokines and HIV-1 env protein
14. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry
15. The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection
16. Role of the first and third extracellular domains of CXCR-4 in human immunodeficiency virus coreceptor activity
17. Effect of mutations in the second extracellular loop of CXCR4 on its utilization by human and feline immunodeficiency viruses
18. Identification of residues of CXCR4 critical for human immunodeficiency virus coreceptor and chemokine receptor activities
19. Substitutions in a homologous region of extracellular loop 2 of CXCR4 and CCR5 alter coreceptor activities for HIV-1 membrane fusion and virus entry
20. Mutagenesis of CXCR4 identifies important domains for human immunodeficiency virus type 1 X4 isolate envelope-mediated membrane fusion and virus entry and reveals cryptic coreceptor activity for R5 isolates
21. N-linked glycosylation of CXCR4 masks coreceptor function for CCR5-dependent human immunodeficiency virus type 1 isolates
22. Core structure of gp41 from the HIV envelope glycoprotein
23. V3 recombinants indicate a central role for CCR5 as a coreceptor in tissue infection by human immunodeficiency virus type 1
24. Molecular determinants of the V3 loop of human immunodeficiency virus type 1 glycoprotein gp120 responsible for controlling cell tropism
25. Macrophage-tropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: Definition of critical amino acids involved in cell tropism
26. Identification of determinants on a dualtropic human immunodeficiency virus type 1 envelope glycoprotein that confer usage of CXCR4
27. The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection
28. Change in coreceptor use coreceptor use correlates with disease progression in HIV-1-infected individuals
29. Specific interaction of CCR5 amino-terminal domain peptides containing sulfo-tyrosines with HIV-1 envelope glycoprotein gp120
30. Mapping the determinants of the CCR5 amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120/CD4 complexes
31. Association between CCR5 genotype and the clinical course of HIV-1 infection
32. HIV-1 coreceptor use: A molecular window into viral tropism
33. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor
34. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor
35. Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1
36. Identification of CXCR4 domains that support co-receptor and chemokine receptor functions
37. Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry
38. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5
39. Activity of different bicyclam derivatives against human immunodeficiency virus depends on their interaction with the CXCR4 chemokine receptor
40. A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5
41. Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry
42. A tyrosine-sulfated peptide based on the N-terminus of CCR5 interacts with a CD4-enhanced epitope of the HIV-1 gp120 envelope glycoprotein and inhibits HIV-1 entry
43. The history of HIV-1 biological phenotypes past, present, and future
44. Dual effect of CCR5 delta 32 gene deletion in HIV-1-infected patients
45. Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor
46. Increased association of glycoprotein 120-CD4 with HIV type 1 coreceptors in the presence of complex-enhanced anti-CD4 monoclonal antibodies
47. Amino acid substitutions in the V3 loop are responsible for adaptation to growth in transformed T-cell lines of a primary human immunodeficiency virus type 1
48. Dissociation of the signalling and antiviral properties of SDF-1-derived small peptides
49. Detection and delineation of CXCR4 (fusin) as an entry and fusion cofactor for T-cell tropic HIV-1 by three different monoclonal antibodies
50. Small molecule inhibitor of HIV-1 cell fusion blocks chemokine receptor-mediated function
51. Inhibition of in vitro and in vivo HIV replication by a distamycin analogue that interferes with chemokine receptor function: A candidate for chemotherapeutic and microbicidal application
52. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression
53. Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1
54. Alteration of HIV-1 infectivity and neutralization by a single amino acid replacement in the V3 loop domain
55. Entry of R5X4 and X4 human immunodeficiency virus type 1 strains is mediated by negatively charged and tyrosine residues in the amino-terminal domain and the second extracellular loop of CXCR4
56. Polymorphisms in the CCR5 genes of African green monkeys and mice implicate specific amino acids in infections by simian and human immunodeficiency viruses
57. Cooperation of multiple CCR5 coreceptors is required for infections by human immunodeficiency virus type 1
58. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
59. Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus
60. Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicyclam AMD3100
61. Evidence for cell-surface association between fusin and the CD4-gp120 complex in human cell lines
62. Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function
63. Evolution of HIV-1 coreceptor usage through interactions with distinct CCR5 and CXCR4 domains
64. Inhibition of human immunodeficiency virus fusion by a monoclonal antibody to a coreceptor (CXCR4) is both cell type and virus strain dependent
65. Rare mutations in a domain crucial for V3-loop structure prevail in replicating HIV from long-term non-progressors
66. Early protective effect of CCR-5 delta 32 heterozygosity on HIV-1 disease progression: Relationship with viral load
67. HIV-1 entry inhibitors: Evading the issue
68. The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression
69. The role of the V3 domain of gp120 in HIV infection
70. The HIV-cell fusion reaction
71. Effect of a single amino acid substitution in the V3 domain of the human immunodeficiency virus type 1: Generation of revertant viruses to overcome defects in infectivity in specific cell types
72. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection
73. Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection
74. Energetics of the HIV gp120-CD4 binding reaction
75. Anti-human immunodeficiency virus type 1 activity of an oligocationic compound mediated via gp120 V3 interactions
76. Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5
77. Analysis of mutations in the V3 domain of gp160 that affect fusion and infectivity
78. Use of murine CXCR-4 as a second receptor by some T-cell-tropic human immunodeficiency viruses
79. Multiple extracellular domains of CCR-5 contribute to human immunodeficiency virus type 1 entry and fusion
80. Alanine substitutions of polar and nonpolar residues in the amino-terminal domain of CCR5 differently impair entry of macrophage-and dualtropic isolates of human immunodeficiency virus type 1
81. The second extracellular loop of CXCR4 is involved in CD4-independent entry of human immunodeficiency virus type 2
82. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding
83. Multiple residues contribute to the inability of murine CCR-5 to function as a coreceptor for macrophage-tropic human immunodeficiency virus type 1 isolates
84. Regions in beta-chemokine receptors CCR5 and CCR2b that determine HIV-1 cofactor specificity
85. Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4
86. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4
87. T-cell-line-tropic human immunodeficiency virus type 1 that is made resistant to stromal cell-derived factor 1alpha contains mutations in the envelope gp120 but does not show a switch in coreceptor use
88. Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1
89. A critical site in the core of the CCR5 chemokine receptor required for binding and infectivity of human immunodeficiency virus type 1
90. Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry
91. A monoclonal antibody (12G5) directed against CXCR-4 inhibits infection with the dual-tropic human immunodeficiency virus type 1 isolate HIV-1(89.6) but not the T-tropic isolate HIV-1(HxB)
92. Pharmacophore identification of a chemokine receptor (CXCR4) antagonist, T22 ([Tyr(5,12),Lys7]-polyphemusin II), which specifically blocks T cell-line-tropic HIV-1 infection
93. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: A strong anti-HIV peptide T140
94. Inhibition of G-protein-coupled receptor function by disruption of transmembrane domain interactions
95. CD4-dependent, antibody sensitive interactions between HIV-1 and its co-receptor CCR5
96. Genetic subtype-independent inhibition of human immunodeficiency virus type 1 replication by CC and CXC chemokines
97. Role of the HIV type 1 glycoprotein 120 V3 loop in determining coreceptor usage
98. CXCR4 sequences involved in coreceptor determination of human immunodeficiency virus type-1 tropism. Unmasking of activity with M-tropic Env glycoproteins
99. Hypervariable region 3 residues of HIV type 1 gp120 involved in CCR5 coreceptor utilization: Therapeutic and prophylactic implications
100. CCR5 HIV-1 coreceptor activity
101. Atomic structure of the ectodomain from HIV-1 gp41
102. The second extracellular loop of CXCR4 determines its function as a receptor for feline immunodeficiency virus
103. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5
104. Dimeric association and segmental variability in the structure of human CD4
105. Interaction of chemokine receptor CCR5 with its ligands: Multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding
106. The HIV-1 envelope glycoproteins: Fusogens, antigens and immunogens
107. The antigenic structure of the human immunodeficiency virus gp120 envelope glycoprotein
108. Marked increase in anti-HIV activity, as well as inhibitory activity against HIV entry mediated by CXCR4, linked to enhancement of the binding ability of tachyplesin analogs to CXCR4
109. Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus type 1 entry?
110. Chemokine coreceptor usage by diverse primary isolates of human immunodeficiency virus type 1
111. Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells